U.S. and European drug regulators have yet to reach a final conclusion about whether a widely prescribed class of type 2 diabetes drugs increases the risk of pancreatic problems. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) launched separate investigations a year ago into the safety of so-called incretin mimetics drugs such as Januvia and Byetta after studies linked the medications to acute pancreatitis and pancreatic cancer. Incretin mimetics, which include GLP-1 receptor agonists and DDP-4 inhibitors, work by increasing the release of insulin after meals and by slowing the absorption of food in the gastrointestinal ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.